A Safety and Efficacy Study to Evaluate AMG 531 Treatment in Subject With Myelodysplastic Syndrome Receiving Revlimid
A Safety and Efficacy Study to Evaluate AMG 531 Treatment in Subject With Myelodysplastic Syndrome Receiving Revlimid
Bio2RDF identifier
NCT00418665
Bio2RDF namespace
clinicaltrials
Bio2RDF uri
http://bio2rdf.org/clinicaltrials:NCT00418665
identifiers.org URI
actual enrollment [clinicaltrials_vocabulary:actual-enrollment]
arm group [clinicaltrials_vocabulary:arm-group]
authority [clinicaltrials_vocabulary:authority]
baseline [clinicaltrials_vocabulary:baseline]
brief summary [clinicaltrials_vocabulary:brief-summary]
This is a dose and sche ...... neous injection for 16 weeks.
brief title [clinicaltrials_vocabulary:brief-title]
A Safety and Efficacy Study to ...... ic Syndrome Receiving Revlimid
clinical result [clinicaltrials_vocabulary:clinical-result]
clinicaltrials_vocabulary:primary outcome [clinicaltrials_vocabulary:clinicaltrials_vocabulary:primary-outcome]
clinicaltrials_vocabulary:secondary outcome [clinicaltrials_vocabulary:clinicaltrials_vocabulary:secondary-outcome]
completion date [clinicaltrials_vocabulary:completion-date]
2010-10-01T00:00:00Z
condition [clinicaltrials_vocabulary:condition]
condition browse [clinicaltrials_vocabulary:condition-browse]
condition mesh [clinicaltrials_vocabulary:condition-mesh]
country [clinicaltrials_vocabulary:country]
download date [clinicaltrials_vocabulary:download-date]
ClinicalTrials.gov processed this data on August 10, 2015
eligibility [clinicaltrials_vocabulary:eligibility]
firstreceived date [clinicaltrials_vocabulary:firstreceived-date]
2007-01-04T00:00:00Z
firstreceived results date [clinicaltrials_vocabulary:firstreceived-results-date]
2010-11-24T00:00:00Z
has expanded access [clinicaltrials_vocabulary:has-expanded-access]
intervention [clinicaltrials_vocabulary:intervention]
intervention browse [clinicaltrials_vocabulary:intervention-browse]
keyword [clinicaltrials_vocabulary:keyword]
Intermediate 1 Myelodysplastic Syndrome
Lenalidomide
Low Platelet Count
Low Risk Myelodysplastic Syndrome
Myelodysplastic Syndrome
lastchanged date [clinicaltrials_vocabulary:lastchanged-date]
2011-01-20T00:00:00Z
lead sponsor [clinicaltrials_vocabulary:lead-sponsor]
link [clinicaltrials_vocabulary:link]
nct id [clinicaltrials_vocabulary:nct-id]
NCT00418665
number of arms [clinicaltrials_vocabulary:number-of-arms]
official title [clinicaltrials_vocabulary:official-title]
A Randomized, Double Blind, Pl ...... (MDS) Receiving Lenalidomide.
org study id [clinicaltrials_vocabulary:org-study-id]
20,060,102
outcome [clinicaltrials_vocabulary:outcome]
overall official [clinicaltrials_vocabulary:overall-official]
overall status [clinicaltrials_vocabulary:overall-status]
oversight [clinicaltrials_vocabulary:oversight]
participant flow [clinicaltrials_vocabulary:participant-flow]
phase [clinicaltrials_vocabulary:phase]
primary completion date [clinicaltrials_vocabulary:primary-completion-date]
2009-03-01T00:00:00Z
reported events [clinicaltrials_vocabulary:reported-events]
responsible party [clinicaltrials_vocabulary:responsible-party]
source [clinicaltrials_vocabulary:source]
start date [clinicaltrials_vocabulary:start-date]
2006-12-01T00:00:00Z
study design [clinicaltrials_vocabulary:study-design]
study type [clinicaltrials_vocabulary:study-type]
url [clinicaltrials_vocabulary:url]
verification date [clinicaltrials_vocabulary:verification-date]
2011-01-01T00:00:00Z
identifier
clinicaltrials:NCT00418665
title
A Safety and Efficacy Study to ...... ic Syndrome Receiving Revlimid
@en